MIdWestOne Financial Group Inc. Sells 6,416 Shares of Jazz Pharmaceuticals PLC $JAZZ

MIdWestOne Financial Group Inc. reduced its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 16.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,855 shares of the specialty pharmaceutical company’s stock after selling 6,416 shares during the quarter. Jazz Pharmaceuticals accounts for approximately 0.6% of MIdWestOne Financial Group Inc.’s investment portfolio, making the stock its 26th largest holding. MIdWestOne Financial Group Inc.’s holdings in Jazz Pharmaceuticals were worth $5,585,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Hilltop National Bank purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $36,000. LRI Investments LLC purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $38,000. Leonteq Securities AG purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $50,000. Danske Bank A S purchased a new position in Jazz Pharmaceuticals in the third quarter valued at about $40,000. Finally, GoalVest Advisory LLC purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $51,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $236.17 on Friday. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32. The firm has a market capitalization of $14.84 billion, a price-to-earnings ratio of -11,802.60, a PEG ratio of 0.21 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The stock’s 50-day simple moving average is $216.77 and its 200-day simple moving average is $188.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion for the quarter. As a group, equities analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rick E. Winningham sold 2,741 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director owned 9,567 shares in the company, valued at $2,311,100.19. The trade was a 22.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 10,741 shares of company stock worth $2,287,143. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JAZZ. Truist Financial set a $256.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company lifted their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Leerink Partners lifted their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Raymond James Financial reiterated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Finally, Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, May 26th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $246.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.